27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Vaxart Inc (NASDAQ: VXRT) has announced new data from the Phase 1 trial evaluating its oral COVID-19 vaccine candidate, dubbed as VXA-CoV2-1.
- Data obtained showed substantial CD8+ T-cell responses against SARS-Cov-2 and showed cross-reactivity against diverse endemic coronaviruses such as 229E, NL63, HKU1, and OC43.
- In a comparative experiment, Phase 1 study data was compared to T-cell responses from volunteers subsequently vaccinated with the Moderna Inc’s (NASDAQ: MRNA) or Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) vaccines, indicating the mRNA vaccines induced fewer T-cell responses.
- “The strength of T-cell responses against both S and N proteins, which we targeted, leads us to believe that VXA-CoV2-1 offers a promising solution to variants,” said Dr. Sean Tucker, chief scientific officer at Vaxart.
- Price Action: VXRT shares up 17.5% at $9.42 in the premarket session on the last check Tuesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!